Role of nerves in neurofibromatosis type 1-related nervous system tumors

1.

P.J. Cimino, D.H. Gutmann, Neurofibromatosis type 1, Handbook of clinical neurology 148, 799–811 (2018) https://doi.org/10.1016/b978-0-444-64076-5.00051-x

2.

J.M. Friedman, Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89, 1–6 (1999)CrossRef

3.

E. Rad, A.R. Tee, Neurofibromatosis type 1: Fundamental insights into cell signalling and cancer. Semin. Cell Dev. Biol. 52, 39–46 (2016). https://doi.org/10.1016/j.semcdb.2016.02.007CrossRef

4.

G.A. Mashour, P.H. Driever, M. Hartmann, S.N. Drissel, T. Zhang, B. Scharf, U. Felderhoff-Müser, S. Sakuma, R.E. Friedrich, R.L. Martuza, V.F. Mautner, A. Kurtz, Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1. Clin. cancer research: official J. Am. Association Cancer Res. 10, 5677–5683 (2004). https://doi.org/10.1158/1078-0432.Ccr-03-0769CrossRef

5.

D.H. Gutmann, R.E. Ferner, R.H. Listernick, B.R. Korf, P.L. Wolters, K.J. Johnson, Neurofibromatosis type 1. Nat. Rev. Dis. Primers 3, 17004 (2017). https://doi.org/10.1038/nrdp.2017.4CrossRef

6.

T. Tucker, P. Wolkenstein, J. Revuz, J. Zeller, J.M. Friedman, Association between benign and malignant peripheral nerve sheath tumors in NF1, Neurology 65, 205–211 (2005) https://doi.org/10.1212/01.wnl.0000168830.79997.13

7.

B.N. Somatilaka, A. Sadek, R.M. McKay, L.Q. Le, Malignant peripheral nerve sheath tumor: models, biology, and translation. Oncogene 41, 2405–2421 (2022). https://doi.org/10.1038/s41388-022-02290-1CrossRef

8.

O.O. Seminog, M.J. Goldacre, Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br. J. Cancer 108, 193–198 (2013). https://doi.org/10.1038/bjc.2012.535CrossRef

9.

G. Blanchard, M.P. Lafforgue, L. Lion-François, I. Kemlin, D. Rodriguez, P. Castelnau, M. Carneiro, P. Meyer, F. Rivier, S. Barbarot, Y. Chaix, Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur. J. Pediatr. neurology: EJPN : official J. Eur. Pediatr. Neurol. Soc. 20, 275–281 (2016). https://doi.org/10.1016/j.ejpn.2015.12.002CrossRef

10.

C.J. Campen, D.H. Gutmann, Optic Pathway Gliomas in Neurofibromatosis Type 1. J. Child. Neurol. 33, 73–81 (2018). https://doi.org/10.1177/0883073817739509CrossRef

11.

F. D’Angelo, M. Ceccarelli, L. Tala, J. Garofano, V. Zhang, F.P. Frattini, G. Caruso, K.D. Lewis, L. Alfaro, G. Bauchet, D. Berzero, M. Cachia, L. Cangiano, J. Capelle, F. de Groot, F. DiMeco, W. Ducray, G. Farah, S. Finocchiaro, C. Goutagny, C. Kamiya-Matsuoka, H. Lavarino, V. Loiseau, C.E. Lorgis, I. Marras, D.H. McCutcheon, S. Nam, V. Ronchi, R. Saletti, J. Seizeur, M. Slopis, F. Suñol, P. Vandenbos, D. Varlet, C. Vidaud, V. Watts, D.E. Tabar, S.K. Reuss, D. Kim, K. Meyronet, H. Mokhtari, K.P. Salvador, M. Bhat, M. Eoli, A. Sanson, Lasorella, A. Iavarone, The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat. Med. 25, 176–187 (2019). https://doi.org/10.1038/s41591-018-0263-8CrossRef

12.

A.H. Zahalka, P.S. Frenette, Nerves in cancer, Nat. Rev. Cancer 20, 143–157 (2020). https://doi.org/10.1038/s41568-019-0237-2CrossRef

13.

S. Deborde, T. Omelchenko, A. Lyubchik, Y. Zhou, S. He, W.F. McNamara, N. Chernichenko, S.Y. Lee, F. Barajas, C.H. Chen, R.L. Bakst, E. Vakiani, S. He, A. Hall, R.J. Wong, Schwann cells induce cancer cell dispersion and invasion. J. Clin. Investig. 126, 1538–1554 (2016). https://doi.org/10.1172/jci82658CrossRef

14.

C. Hutchings, J.A. Phillips, M.B.A. Djamgoz, Nerve input to tumours: Pathophysiological consequences of a dynamic relationship. Biochim. Biophys. Acta Rev. Cancer 1874, 188411 (2020). https://doi.org/10.1016/j.bbcan.2020.188411CrossRef

15.

H.D. Reavis, H.I. Chen, R. Drapkin, Tumor Innervation: Cancer Has Some Nerve. Trends Cancer 6, 1059–1067 (2020). https://doi.org/10.1016/j.trecan.2020.07.005CrossRef

16.

C. Magnon, S.J. Hall, J. Lin, X. Xue, L. Gerber, S.J. Freedland, P.S. Frenette, Autonomic nerve development contributes to prostate cancer progression. Sci. (New York N Y ) 341, 1236361 (2013). https://doi.org/10.1126/science.1236361CrossRef

17.

H.C. Ko, V. Gupta, W.F. Mourad, K.S. Hu, L.B. Harrison, P.M. Som, R.L. Bakst, A contouring guide for head and neck cancers with perineural invasion. Pract. Radiat. Oncol. 4, e247–e258 (2014). https://doi.org/10.1016/j.prro.2014.02.001CrossRef

18.

G. Rademakers, N. Vaes, S. Schonkeren, A. Koch, K.A. Sharkey, V. Melotte, The role of enteric neurons in the development and progression of colorectal cancer, Biochim. Biophys. Acta Rev. Cancer 1868, 420–434 (2017). https://doi.org/10.1016/j.bbcan.2017.08.003CrossRef

19.

S. Faulkner, P. Jobling, B. March, C.C. Jiang, H. Hondermarck, Tumor Neurobiology and the War of Nerves in Cancer. Cancer Discov. 9, 702–710 (2019). https://doi.org/10.1158/2159-8290.Cd-18-1398CrossRef

20.

C. Jiang, R.M. McKay, L.Q. Le, Tumorigenesis in neurofibromatosis type 1: role of the microenvironment. Oncogene 40, 5781–5787 (2021). https://doi.org/10.1038/s41388-021-01979-zCrossRef

21.

N.H. Boyd, A.N. Tran, J.D. Bernstock, T. Etminan, A.B. Jones, G.Y. Gillespie, G.K. Friedman, A.B. Hjelmeland, Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics 11, 665–683 (2021). https://doi.org/10.7150/thno.41692CrossRef

22.

Y.P. Hsueh, Neurofibromin signaling and synapses. J. Biomed. Sci. 14, 461–466 (2007). https://doi.org/10.1007/s11373-007-9158-2CrossRef

23.

A.B. Trovó-Marqui, E.H. Tajara, Neurofibromin: a general outlook. Clin. Genet. 70, 1–13 (2006). https://doi.org/10.1111/j.1399-0004.2006.00639.xCrossRef

24.

J.A. Brown, K.A. Diggs-Andrews, S.M. Gianino, D.H. Gutmann, Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner, Mol. Cell. Neurosci. 49, 13–22 (2012) https://doi.org/10.1016/j.mcn.2011.08.008

25.

B. Rico, H.E. Beggs, D. Schahin-Reed, N. Kimes, A. Schmidt, L.F. Reichardt, Control of axonal branching and synapse formation by focal adhesion kinase. Nat. Neurosci. 7, 1059–1069 (2004). https://doi.org/10.1038/nn1317CrossRef

26.

E. Robles, T.M. Gomez, Focal adhesion kinase signaling at sites of integrin-mediated adhesion controls axon pathfinding. Nat. Neurosci. 9, 1274–1283 (2006). https://doi.org/10.1038/nn1762CrossRef

27.

M. Endo, T. Yamashita, Inactivation of Ras by p120GAP via focal adhesion kinase dephosphorylation mediates RGMa-induced growth cone collapse. J. neuroscience: official J. Soc. Neurosci. 29, 6649–6662 (2009). https://doi.org/10.1523/jneurosci.0927-09.2009CrossRef

28.

S. Woo, D.J. Rowan, T.M. Gomez, Retinotopic mapping requires focal adhesion kinase-mediated regulation of growth cone adhesion. J. neuroscience: official J. Soc. Neurosci. 29, 13981–13991 (2009). https://doi.org/10.1523/jneurosci.4028-09.2009CrossRef

29.

F. Kweh, M. Zheng, E. Kurenova, M. Wallace, V. Golubovskaya, W.G. Cance, Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase. Mol. Carcinog. 48, 1005–1017 (2009). https://doi.org/10.1002/mc.20552CrossRef

30.

T. Ozawa, N. Araki, S. Yunoue, H. Tokuo, L. Feng, S. Patrakitkomjorn, T. Hara, Y. Ichikawa, K. Matsumoto, K. Fujii, H. Saya, The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J. Biol. Chem. 280, 39524–39533 (2005). https://doi.org/10.1074/jbc.M503707200CrossRef

31.

P.I. Tsai, M. Wang, H.H. Kao, Y.J. Cheng, J.A. Walker, R.H. Chen, C.T. Chien, Neurofibromin mediates FAK signaling in confining synapse growth at Drosophila neuromuscular junctions. J. neuroscience: official J. Soc. Neurosci. 32, 16971–16981 (2012). https://doi.org/10.1523/jneurosci.1756-12.2012CrossRef

32.

Y.L. Lin, Y.P. Hsueh, Neurofibromin interacts with CRMP-2 and CRMP-4 in rat brain. Biochem. Biophys. Res. Commun. 369, 747–752 (2008). https://doi.org/10.1016/j.bbrc.2008.02.095CrossRef

33.

S. Patrakitkomjorn, D. Kobayashi, T. Morikawa, M.M. Wilson, N. Tsubota, A. Irie, T. Ozawa, M. Aoki, N. Arimura, K. Kaibuchi, H. Saya, N. Araki, Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2. J. Biol. Chem. 283, 9399–9413 (2008). https://doi.org/10.1074/jbc.M708206200CrossRef

34.

M. Bergoug, M. Doudeau, F. Godin, C. Mosrin, B. Vallée, H. Bénédetti, Neurofibromin Struct. Funct. Regul. Cells 9, (2020) https://doi.org/10.3390/cells9112365

35.

M.E. Önger, B. Delibaş, A.P. Türkmen, E. Erener, B.Z. Altunkaynak, S. Kaplan, The role of growth factors in nerve regeneration. Drug discoveries & therapeutics 10, 285–291 (2017). https://doi.org/10.5582/ddt.2016.01058CrossRef

36.

K. Cichowski, S. Santiago, M. Jardim, B.W. Johnson, T. Jacks, Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev. 17, 449–454 (2003). https://doi.org/10.1101/gad.1054703CrossRef

37.

Y.Y. Zhang, T.A. Vik, J.W. Ryder, E.F. Srour, T. Jacks, K. Shannon, D.W. Clapp, Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med. 187, 1893–1902 (1998). https://doi.org/10.1084/jem.187.11.1893CrossRef

38.

K.S. Vogel, C.I. Brannan, N.A. Jenkins, N.G. Copeland, L.F. Parada, Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons. Cell 82, 733–742 (1995). https://doi.org/10.1016/0092-8674(95)90470-0CrossRef

39.

S.L. Carroll, M.S. Stonecypher, Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. J. Neuropathol. Exp. Neurol. 64, 1–9 (2005). https://doi.org/10.1093/jnen/64.1.1CrossRef

40.

Y. Kawachi, H. Maruyama, Y. Ishitsuka, Y. Fujisawa, J. Furuta, Y. Nakamura, E. Ichikawa, M. Furumura, F. Otsuka, NF1 gene silencing induces upregulation of vascular endothelial growth factor expression in both Schwann and non-Schwann cells. Exp. Dermatol. 22, 262–265 (2013). https://doi.org/10.1111/exd.12115CrossRef

41.

T.A. Mitsiadis, M. Salmivirta, T. Muramatsu, H. Muramatsu, H. Rauvala, E. Lehtonen, M. Jalkanen, I. Thesleff, Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Dev. (Cambridge England) 121, 37–51 (1995). https://doi.org/10.1242/dev.121.1.37CrossRef

42.

T. Muramatsu, Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J. BioChem. 132, 359–371 (2002). https://doi.org/10.1093/oxfordjournals.jbchem.a003231CrossRef

43.

I. Atallah, A.M. Cieza Rivera, O.M. Rivero Lezcano, L. Tascón-González, C. González-Cortés, C. Diez, T. Tascón, Fernández-Villa, V. Martín, Increased serum concentrations of estrogen-induced growth factors Midkine and FGF2 in NF1 patients with plexiform neurofibroma. Am. J. translational Res. 14, 3180–3188 (2022)

44.

X. Guo, Y. Pan, M. Xiong, S. Sanapala, C. Anastasaki, O. Cobb, S. Dahiya, D.H. Gutmann, Midkine activation of CD8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat. Commun. 11, 2177 (2020). https://doi.org/10.1038/s41467-020-15770-3CrossRef

45.

A. Moutal, E.T. Dustrude, R. Khanna, Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1, Mol. Neurobiol. 54, 3342–3349 (2017) https://doi.org/10.1007/s12035-016-9907-1

46.

Y. Wang, J.M. Brittain, S.M. Wilson, C.M. Hingtgen, R. Khanna, Altered calcium currents and axonal growth in NF1 haploinsufficient mice, Transl. Neurosci. 1, 106–114 (2010). https://doi.org/10.2478/v10134-010-0025-8CrossRef

47.

C.M. Johannessen, E.E. Reczek, M.F. James, H. Brems, E. Legius, K. Cichowski, The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. U.S.A. 102, 8573–8578 (2005). https://doi.org/10.1073/pnas.0503224102CrossRef

48.

M. Rosner, M. Hanneder, N. Siegel, A. Valli, C. Fuchs, M. Hengstschläger, The mTOR pathway and its role in human genetic diseases. Mutat. Res. 659, 284–292 (2008). https://doi.org/10.1016/j.mrrev.2008.06.001CrossRef

49.

J. Bockaert, P. Marin, mTOR in Brain Physiology and Pathologies. Physiol. Rev. 95, 1157–1187 (2015). https://doi.org/10.1152/physrev.00038.2014CrossRef

50.

P.Y. Martin, S. Doly, A.M. Hamieh, E. Chapuy, V. Canale, M. Drop, S. Chaumont-Dubel, X. Bantreil, F. Lamaty, A.J. Bojarski, P. Zajdel, A. Eschalier, P. Marin, C. Courteix, mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. Prog. Neurobiol. 193, 101846 (2020). https://doi.org/10.1016/j.pneurobio.2020.101846CrossRef

51.

E. Doucet, K. Grychowska, P. Zajdel, J. Bockaert, P. Marin, C. Bécamel, Blockade of Serotonin 5-HT(6) Receptor Constitutive Activity Alleviates Cognitive Deficits in a Preclinical Model of Neurofibromatosis Type 1, Int. J. Mol. Sci. 22, (2021) https://doi.org/10.3390/ijms221810178

52.

M.J. Ribeiro, I.R. Violante, I. Bernardino, R.A. Edden, M. Castelo-Branco, Abnormal relationship between GABA, neurophysiology and impulsive behavior in neurofibromatosis type 1. Cortex 64, 194–208 (2015) https://doi.org/10.1016/j.cortex.2014.10.019

53.

I.R. Violante, M. Patricio, I. Bernardino, J. Rebola, A.J. Abrunhosa, N. Ferreira, M. Castelo-Branco, GABA deficiency in NF1: A multimodal [11 C]-flumazenil and spectroscopy study. Neurology 87, 897–904 (2016). https://doi.org/10.1212/wnl.0000000000003044CrossRef

54.

R.M. Costa, N.B. Federov, J.H. Kogan, G.G. Murphy, J. Stern, M. Ohno, R. Kucherlapati, T. Jacks, A.J. Silva, Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526–530 (2002). https://doi.org/10.1038/nature711CrossRef

55.

Y. Cui, R.M. Costa, G.G. Murphy, Y. Elgersma, Y. Zhu, D.H. Gutmann, L.F. Parada, I. Mody, A.J. Silva, Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135, 549–560 (2008). https://doi.org/10.1016/j.cell.2008.09.060CrossRef

56.

S. Hilfiker, V.A. Pieribone, A.J. Czernik, H.T. Kao, G.J. Augustine, P. Greengard, Synapsins as regulators of neurotransmitter release. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 269–279 (1999). https://doi.org/10.1098/rstb.1999.0378CrossRef

57.

I.R. Violante, M.J. Ribeiro, R.A. Edden, P. Guimarães, I. Bernardino, J. Rebola, G. Cunha, E. Silva, M. Castelo-Branco, GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. Brain: a journal of neurology 136, 918–925 (2013). https://doi.org/10.1093/brain/aws368CrossRef

58.

Y. Wang, G.D. Nicol, D.W. Clapp, C.M. Hingtgen, Sensory neurons from Nf1 haploinsufficient mice exhibit increased excitability. J. Neurophysiol. 94, 3670–3676 (2005). https://doi.org/10.1152/jn.00489.2005CrossRef

59.

J.H. Duan, Y. Wang, D. Duarte, M.R. Vasko, G.D. Nicol, C.M. Hingtgen, Ras signaling pathways mediate NGF-induced enhancement of excitability of small-diameter capsaicin-sensitive sensory neurons from wildtype but not Nf1+/- mice. Neurosci. Lett. 496, 70–74 (2011). https://doi.org/10.1016/j.neulet.2011.03.083CrossRef

60.

K.E. Hodgdon, C.M. Hingtgen, G.D. Nicol, Dorsal root ganglia isolated from Nf1+/- mice exhibit increased levels of mRNA expression of voltage-dependent sodium channels. Neuroscience 206, 237–244 (2012). https://doi.org/10.1016/j.neuroscience.2011.12.045CrossRef

61.

J.H. Duan, K.E. Hodgdon, C.M. Hingtgen, G.D. Nicol, N-type calcium current, Cav2.2, is enhanced in small-diameter sensory neurons isolated from Nf1+/- mice. Neuroscience 270, 192–202 (2014). https://doi.org/10.1016/j.neuroscience.2014.04.021CrossRef

62.

C. Anastasaki, J. Mo, J.K. Chen, J. Chatterjee, Y. Pan, S.M. Scheaffer, O. Cobb, M. Monje, L.Q. Le, D.H. Gutmann, Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1. Nat. Commun. 13, 2785 (2022). https://doi.org/10.1038/s41467-022-30466-6CrossRef

63.

J.S. Nix, J. Blakeley, F.J. Rodriguez, An update on the central nervous system manifestations of neurofibromatosis type 1. Acta Neuropathol. 139, 625–641 (2020). https://doi.org/10.1007/s00401-019-02002-2CrossRef

64.

M. Bayat, A. Bayat, Neurological manifestations of neurofibromatosis: a review. Neurol. Sci. 41, 2685–2690 (2020) https://doi.org/10.1007/s10072-020-04400-x

65.

K.I. Ly, J.O. Blakeley, The diagnosis and management of neurofibromatosis Type 1. Med. Clin. North Am. 103, 1035–1054 (2019) https://doi.org/10.1016/j.mcna.2019.07.004

66.

A. Cannon, M.J. Chen, P. Li, K.P. Boyd, A. Theos, D.T. Redden, B. Korf, Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet J. Rare Dis. 13, 31 (2018). https://doi.org/10.1186/s13023-018-0772-zCrossRef

67.

L. Dugoff, E. Sujansky, Neurofibromatosis type 1 and pregnancy. Am. J. Med. Genet. 66, 7–10 (1996) https://doi.org/10.1002/(sici)1096-8628(19961202)66:1(7::Aid-ajmg2)3.0.Co;2-r

68.

R.E. Ferner, Neurofibromatosis 1. Eur. J. Hum. Genet 15, 131–138 (2007). https://doi.org/10.1038/sj.ejhg.5201676CrossRef

69.

D.G. Evans, M.E. Baser, J. McGaughran, S. Sharif, E. Howard, A. Moran, Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 39, 311–314 (2002). https://doi.org/10.1136/jmg.39.5.311CrossRef

70.

P. de Robles, K.M. Fiest, A.D. Frolkis, T. Pringsheim, C. Atta, C.St Germaine-Smith, L. Day, D. Lam, N. Jette, The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro-oncology 17, 776–783 (2015). https://doi.org/10.1093/neuonc/nou283CrossRef

71.

A. Rosenfeld, R. Listernick, J. Charrow, S. Goldman, Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Child’s Nerv. system: ChNS : official J. Int. Soc. Pediatr. Neurosurg. 26, 663–667 (2010). https://doi.org/10.1007/s00381-009-1024-2CrossRef

72.

D.H. Gutmann, S.A. Rasmussen, P. Wolkenstein, M.M. MacCollin, A. Guha, P.D. Inskip, K.N. North, M. Poyhonen, P.H. Birch, J.M. Friedman, Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59, 759–761 (2002). https://doi.org/10.1212/wnl.59.5.759CrossRef

73.

H.S. Venkatesh, T.B. Johung, V. Caretti, A. Noll, Y. Tang, S. Nagaraja, E.M. Gibson, C.W. Mount, J. Polepalli, S.S. Mitra, P.J. Woo, R.C. Malenka, H. Vogel, M. Bredel, P. Mallick, and M. Monje, Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion. Cell 161, 803–816 (2015). https://doi.org/10.1016/j.cell.2015.04.012CrossRef

74.

H.S. Venkatesh, L.T. Tam, P.J. Woo, J. Lennon, S. Nagaraja, S.M. Gillespie, J. Ni, D.Y. Duveau, P.J. Morris, J.J. Zhao, C.J. Thomas, M. Monje, Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature 549, 533–537 (2017). https://doi.org/10.1038/nature24014CrossRef

75.

H.S. Venkatesh, W. Morishita, A.C. Geraghty, D. Silverbush, S.M. Gillespie, M. Arzt, L.T. Tam, C. Espenel, A. Ponnuswami, L. Ni, P.J. Woo, K.R. Taylor, A. Agarwal, A. Regev, D. Brang, H. Vogel, S. Hervey-Jumper, D.E. Bergles, M.L. Suvà, R.C. Malenka, M. Monje, Electrical and synaptic integration of glioma into neural circuits. Nature 573, 539–545 (2019). https://doi.org/10.1038/s41586-019-1563-yCrossRef

76.

V. Venkataramani, D.I. Tanev, C. Strahle, A. Studier-Fischer, L. Fankhauser, T. Kessler, C. Körber, M. Kardorff, M. Ratliff, R. Xie, H. Horstmann, M. Messer, S.P. Paik, J. Knabbe, F. Sahm, F.T. Kurz, A.A. Acikgöz, F. Herrmannsdörfer, A. Agarwal, D.E. Bergles, A. Chalmers, H. Miletic, S. Turcan, C. Mawrin, D. Hänggi, H.K. Liu, W. Wick, F. Winkler, T. Kuner, Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573, 532–538 (2019). https://doi.org/10.1038/s41586-019-1564-xCrossRef

77.

A. Comba, S.M. Faisal, P.J. Dunn, A.E. Argento, T.C. Hollon, W.N. Al-Holou, M.L. Varela, D.B. Zamler, G.L. Quass, P.F. Apostolides, C. Abel 2nd, C.E. Brown, P.E. Kish, A. Kahana, C.G. Kleer, S. Motsch, M.G. Castro, P.R. Lowenstein, Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nat. Commun. 13, 3606 (2022). https://doi.org/10.1038/s41467-022-31340-1CrossRef

78.

A. Comba, S.M. Faisal, M.L. Varela, T. Hollon, W.N. Al-Holou, Y. Umemura, F.J. Nunez, S. Motsch, M.G. Castro, P.R. Lowenstein, Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. Front. Oncol. 11, 703764 (2021). https://doi.org/10.3389/fonc.2021.703764CrossRef

79.

A. Mega, M. Hartmark Nilsen, L.W. Leiss, N.P. Tobin, H. Miletic, L. Sleire, C. Strell, S. Nelander, C. Krona, D. Hägerstrand, P. Enger, M. Nistér, A. Östman, Astrocytes enhance glioblastoma growth. Glia 68, 316–327 (2020). https://doi.org/10.1002/glia.23718CrossRef

80.

D. Hambardzumyan, D.H. Gutmann, H. Kettenmann, The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20–27 (2016). https://doi.org/10.1038/nn.4185CrossRef

81.

J. Wei, P. Chen, P. Gupta, M. Ott, D. Zamler, C. Kassab, K.P. Bhat, M.A. Curran, J.F. de Groot, A.B. Heimberger, Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro-oncology 22, 180–194 (2020). https://doi.org/10.1093/neuonc/noz212CrossRef

82.

J.C. Carlson, M. Cantu Gutierrez, B. Lozzi, E. Huang-Hobbs, W.D. Turner, B. Tepe, Y. Zhang, A.M. Herman, G. Rao, C.J. Creighton, J.D. Wythe, B. Deneen, Identification of diverse tumor endothelial cell populations in malignant glioma. Neuro-oncology 23, 932–944 (2021). https://doi.org/10.1093/neuonc/noaa297CrossRef

83.

D. Cahill, S. Turcan, Origin of Gliomas. Semin. Neurol. 38, 5–10 (2018). https://doi.org/10.1055/s-0037-1620238CrossRef

84.

A.E.S. Watson, K. Goodkey, T. Footz, A. Voronova, Regulation of CNS precursor function by neuronal chemokines. Neurosci. Lett. 715, 134533 (2020). https://doi.org/10.1016/j.neulet.2019.134533CrossRef

85.

Z.Q. Li, Z.Y. Yan, F.J. Lan, Y.Q. Dong, Y. Xiong, Suppression of NLRP3 inflammasome attenuates stress-induced depression-like behavior in NLGN3-deficient mice. Biochem. Biophys. Res. Commun. 501, 933–940 (2018) https://doi.org/10.1016/j.bbrc.2018.05.085

86.

C. Davey, A. Tallafuss, P. Washbourne, Differential expression of neuroligin genes in the nervous system of zebrafish, Dev. Dyn. 239, 703–714 (2010) https://doi.org/10.1002/dvdy.22195

87.

R. Liu, X.P. Qin, Y. Zhuang, Y. Zhang, H.B. Liao, J.C. Tang, M.X. Pan, F.F. Zeng, Y. Lei, R.X. Lei, S. Wang, A.C. Liu, J. Chen, Z.F. Zhang, D. Zhao, S.L. Wu, R.Z. Liu, Z.F. Wang, Q. Wan, Glioblastoma recurrence correlates with NLGN3 levels. Cancer Med. 7, 2848–2859 (2018). https://doi.org/10.1002/cam4.1538CrossRef

88.

V. Serafim Junior, G.M.M. Fernandes, J.G. Oliveira-Cucolo, E.C. Pavarino, E.M. Goloni-Bertollo, Role of Tropomyosin-related kinase B receptor and brain-derived neurotrophic factor in cancer. Cytokine 136, 155270 (2020). https://doi.org/10.1016/j.cyto.2020.155270CrossRef

89.

J. Xiong, L. Zhou, Y. Lim, M. Yang, Y.H. Zhu, Z.W. Li, F.H. Zhou, Z.C. Xiao, X.F. Zhou, Mature BDNF promotes the growth of glioma cells in vitro. Oncol. Rep. 30, 2719–2724 (2013). https://doi.org/10.3892/or.2013.2746CrossRef

90.

S.H. Jiang, L.P. Hu, X. Wang, J. Li, Z.G. Zhang, Neurotransmitters: emerging targets in cancer. Oncogene 39, 503–515 (2020). https://doi.org/10.1038/s41388-019-1006-0CrossRef

91.

T.W. Hodo, M.T.P. de Aquino, A. Shimamoto, A. Shanker, Critical Neurotransmitters in the Neuroimmune Network. Front. Immunol. 11, 1869 (2020). https://doi.org/10.3389/fimmu.2020.01869CrossRef

92.

K.L. Ligon, E. Huillard, S. Mehta, S. Kesari, H. Liu, J.A. Alberta, R.M. Bachoo, M. Kane, D.N. Louis, R.A. Depinho, D.J. Anderson, C.D. Stiles, D.H. Rowitch, Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53, 503–517 (2007). https://doi.org/10.1016/j.neuron.2007.01.009CrossRef

93.

A.J. Walker, T. Card, T.E. Bates, K. Muir, Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. Br. J. Cancer 104, 193–197 (2011). https://doi.org/10.1038/sj.bjc.6605996CrossRef

94.

J. Li, S. Zhu, D. Kozono, K. Ng, D. Futalan, Y. Shen, J.C. Akers, T. Steed, D. Kushwaha, M. Schlabach, B.S. Carter, C.H. Kwon, F. Furnari, W. Cavenee, S. Elledge, C.C. Chen, Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget 5, 882–893 (2014). https://doi.org/10.18632/oncotarget.1801CrossRef

95.

M. Tonini, L. Cipollina, E. Poluzzi, F. Crema, G.R. Corazza, F. De Ponti, Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 19, 379–390 (2004). https://doi.org/10.1111/j.1365-2036.2004.01867.xCrossRef

96.

A.S. Chi, R.S. Tarapore, M.D. Hall, N. Shonka, S. Gardner, Y. Umemura, A. Sumrall, Z. Khatib, S. Mueller, C. Kline, W. Zaky, S. Khatua, S.P. Weathers, Y. Odia, T.N. Niazi, D. Daghistani, I. Cherrick, D. Korones, M.A. Karajannis, X.T. Kong, J. Minturn, A. Waanders, I. Arillaga-Romany, T. Batchelor, P.Y. Wen, K. Merdinger, L. Schalop, M. Stogniew, J.E. Allen, W. Oster, M.P. Mehta, Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J. Neurooncol. 145, 97–105 (2019). https://doi.org/10.1007/s11060-019-03271-3CrossRef

97.

I. Arrillaga-Romany, A.S. Chi, J.E. Allen, W. Oster, P.Y. Wen, T.T. Batchelor, A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 8, 79298–79304 (2017). https://doi.org/10.18632/oncotarget.17837CrossRef

98.

J.E. Allen, G. Krigsfeld, P.A. Mayes, L. Patel, D.T. Dicker, A.S. Patel, N.G. Dolloff, E. Messaris, K.A. Scata, W. Wang, J.Y. Zhou, G.S. Wu, and W.S. El-Deiry, Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci. Transl. Med. 5, 171ra117 (2013). https://doi.org/10.1126/scitranslmed.3004828CrossRef

99.

A. Arce-Sillas, E. Sevilla-Reyes, D.D. Álvarez-Luquín, A. Guevara-Salinas, M.C. Boll, C.A. Pérez-Correa, A.V. Vivas-Almazan, U. Rodríguez-Ortiz, C. Castellanos Barba, M. Hernandez, G. Fragoso, E. Sciutto, G. Cárdenas, and L.V. Adalid-Peralta, Expression of dopamine receptors in immune regulatory cells. Neuroimmunomodulation 26, 159–166 (2019). https://doi.org/10.1159/000501187CrossRef

100.

F. McKenna, P.J. McLaughlin, B.J. Lewis, G.C. Sibbring, J.A. Cummerson, D. Bowen-Jones, R.J. Moots, Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132, 34–40 (2002). https://doi.org/10.1016/s0165-5728(02)00280-1CrossRef

101.

J.M. Beaulieu, R.R. Gainetdinov, The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63, 182–217 (2011). https://doi.org/10.1124/pr.110.002642CrossRef

102.

K. Bhat, M. Saki, F. Cheng, L. He, L. Zhang, A. Ioannidis, D. Nathanson, J. Tsang, S.J. Bensinger, P.L. Nghiemphu, T.F. Cloughesy, L.M. Liau, H.I. Kornblum, F. Pajonk, Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. J. Natl Cancer Inst. 113, 1094–1104 (2021). https://doi.org/10.1093/jnci/djab018CrossRef

103.

L.F. Mohammad-Zadeh, L. Moses, S.M. Gwaltney-Brant, Serotonin: a review. J. Vet. Pharmacol. Ther. 31, 187–199 (2008). https://doi.org/10.1111/j.1365-2885.2008.00944.xCrossRef

104.

D. Sarrouilhe, J. Clarhaut, N. Defamie, M. Mesnil, Serotonin and cancer: what is the link? Curr. Mol. Med. 15, 62–77 (2015). https://doi.org/10.2174/1566524015666150114113411CrossRef

105.

G. Fouquet, T. Coman, O. Hermine, F. Côté, Serotonin, hematopoiesis and stem cells. Pharmacol. Res. 140, 67–74 (2019). https://doi.org/10.1016/j.phrs.2018.08.005CrossRef

106.

D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena, P.P. Humphrey, International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157–203 (1994)

107.

A. Merzak, S. Koochekpour, M.P. Fillion, G. Fillion, G.J. Pilkington, Expression of serotonin receptors in human fetal astrocytes and glioma cell lines: a possible role in glioma cell proliferation and migration, Brain research. Mol. Brain Res. 41, 1–7 (1996). https://doi.org/10.1016/0169-328x(96)00058-7CrossRef

108.

B. Abadi, Y. Shahsavani, M. Faramarzpour, N. Rezaei, H.R. Rahimi, Antidepressants with anti-tumor potential in treating glioblastoma: A narrative review. Fundam. Clin. Pharmacol. 36, 35–48 (2022). https://doi.org/10.1111/fcp.12712CrossRef

109.

K.H. Liu, S.T. Yang, Y.K. Lin, J.W. Lin, Y.H. Lee, J.Y. Wang, C.J. Hu, E.Y. Lin, S.M. Chen, C.K. Then, S.C. Shen, Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis. Oncotarget 6, 5088–5101 (2015). https://doi.org/10.18632/oncotarget.3243CrossRef

110.

V.C. Chen, Y.H. Hsieh, L.J. Chen, T.C. Hsu, B.S. Tzang, Escitalopram oxalate induces apoptosis in U-87MG cells and autophagy in GBM8401 cells. J. Cell. Mol. Med. 22, 1167–1178 (2018). https://doi.org/10.1111/jcmm.13372CrossRef

111.

C. Shi, N. Lamba, L.J. Zheng, D. Cote, Q.R. Regestein, C.M. Liu, Q. Tran, S. Routh, T.R. Smith, R.A. Mekary, M.L.D. Broekman, Depression and survival of glioma patients: A systematic review and meta-analysis. Clin. Neurol. Neurosurg. 172, 8–19 (2018). https://doi.org/10.1016/j.clineuro.2018.06.016CrossRef

112.

S. Otto-Meyer, R. DeFaccio, C. Dussold, E. Ladomersky, L. Zhai, K.L. Lauing, L.R. Bollu, C. Amidei, R.V. Lukas, D.M. Scholtens, D.A. Wainwright, A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors. Brain Behav. Immun. Health 2, (2020) https://doi.org/10.1016/j.bbih.2019.100025

113.

A. Jussofie, V. Reinhardt, R. Kalff, GABA binding sites: their density, their affinity to muscimol and their behaviour against neuroactive steroids in human gliomas of different degrees of malignancy. J. Neural Transm. Gen. Sections 96, 233–241 (1994). https://doi.org/10.1007/bf01294790CrossRef

114.

A. Blanchart, R. Fernando, M. Häring, N. Assaife-Lopes, R.A. Romanov, M. Andäng, T. Harkany, P. Ernfors, Endogenous GAB(AA) receptor activity suppresses glioma growth. Oncogene 36, 777–786 (2017). https://doi.org/10.1038/onc.2016.245CrossRef

115.

S. Han, Y. Liu, S.J. Cai, M. Qian, J. Ding, M. Larion, M.R. Gilbert, C. Yang, IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br. J. Cancer 122, 1580–1589 (2020). https://doi.org/10.1038/s41416-020-0814-xCrossRef

116.

L. Dang, K. Yen, E.C. Attar, IDH mutations in cancer and progress toward development of targeted therapeutics. Annals of oncology: official journal of the European Society for Medical Oncology 27, 599–608 (2016). https://doi.org/10.1093/annonc/mdw013CrossRef

117.

T. Gong, X. Zhang, X. Wei, S. Yuan, M.G. Saleh, Y. Song, R.A. Edden, G. Wang, GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo. Neurochem. Int. 141, 104889 (2020). https://doi.org/10.1016/j.neuint.2020.104889CrossRef

118.

A. Rubio-Casillas, A. Fernández-Guasti, The dose makes the poison: from glutamate-mediated neurogenesis to neuronal atrophy and depression. Rev. Neurosci. 27, 599–622 (2016). https://doi.org/10.1515/revneuro-2015-0066CrossRef

119.

N. Nakamichi, T. Takarada, Y. Yoneda, Neurogenesis mediated by gamma-aminobutyric acid and glutamate signaling. J. Pharmacol. Sci. 110, 133–149 (2009). https://doi.org/10.1254/jphs.08r03crCrossRef

120.

Z. Pei, K.C. Lee, A. Khan, G. Erisnor, H.Y. Wang, Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression. Biochem. Pharmacol. 176, 113814 (2020). https://doi.org/10.1016/j.bcp.2020.113814CrossRef

121.

A. Reiner, J. Levitz, Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron 98, 1080–1098 (2018). https://doi.org/10.1016/j.neuron.2018.05.018CrossRef

122.

S.S. Shin, J. Namkoong, B.A. Wall, R. Gleason, H.J. Lee, S. Chen, Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res. 21, 368–378 (2008). https://doi.org/10.1111/j.1755-148X.2008.00452.xCrossRef

123.

F. Gardoni, J. Stanic, D. Scheggia, A. Benussi, B. Borroni and M. Di Luca, NMDA and AMPA Receptor Autoantibodies in Brain Disorders: From Molecular Mechanisms to Clinical Features. Cells 10 (2021) https://doi.org/10.3390/cells10010077

124.

S. Ishiuchi, K. Tsuzuki, Y. Yoshida, N. Yamada, N. Hagimura, H. Okado, A. Miwa, H. Kurihara, Y. Nakazato, M. Tamura, T. Sasaki, S. Ozawa, Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 8, 971–978 (2002). https://doi.org/10.1038/nm746CrossRef

125.

C.M. Niswender, P.J. Conn, Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322 (2010). https://doi.org/10.1146/annurev.pharmtox.011008.145533CrossRef

126.

T. Takano, J.H. Lin, G. Arcuino, Q. Gao, J. Yang, M. Nedergaard, Glutamate release promotes growth of malignant gliomas. Nat. Med. 7, 1010–1015 (2001). https://doi.org/10.1038/nm0901-1010CrossRef

127.

L.J. Yu, B.A. Wall, J. Wangari-Talbot, S. Chen, Metabotropic glutamate receptors in cancer. Neuropharmacology 115, 193–202 (2017). https://doi.org/10.1016/j.neuropharm.2016.02.011CrossRef

128.

L. Iacovelli, A. Arcella, G. Battaglia, S. Pazzaglia, E. Aronica, P. Spinsanti, A. Caruso, E. De Smaele, A. Saran, A. Gulino, M. D’Onofrio, F. Giangaspero, F. Nicoletti, Pharmacological activation of mGlu4 metabotropic glutamate receptors inhibits the growth of medulloblastomas. J. neuroscience: official J. Soc. Neurosci. 26, 8388–8397 (2006). https://doi.org/10.1523/jneurosci.2285-06.2006CrossRef

129.

C. Zhang, X.R. Yuan, H.Y. Li, Z.J. Zhao, Y.W. Liao, X.Y. Wang, J. Su, S.S. Sang, Q. Liu, Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway. Cell. Physiol. Biochem. 35, 419–432 (2015) https://doi.org/10.1159/000369707

130.

M. D’Onofrio, A. Arcella, V. Bruno, R.T. Ngomba, G. Battaglia, V. Lombari, G. Ragona, A. Calogero, F. Nicoletti, Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J. Neurochem. 84, 1288–1295 (2003). https://doi.org/10.1046/j.1471-4159.2003.01633.xCrossRef

131.

M.S.L. Pereira, F. Klamt, C.C. Thomé, P.V. Worm, D.L. de Oliveira, Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas. Oncotarget 8, 22279–22298 (2017). https://doi.org/10.18632/oncotarget.15299CrossRef

132.

P.F. Behrens, H. Langemann, R. Strohschein, J. Draeger, J. Hennig, Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J. Neurooncol. 47, 11–22 (2000). https://doi.org/10.1023/a:1006426917654CrossRef

133.

R. Listernick, R.E. Ferner, G.T. Liu, D.H. Gutmann, Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann. Neurol. 61, 189–198 (2007). https://doi.org/10.1002/ana.21107CrossRef

134.

G.C. Daginakatte, D.H. Gutmann, Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum. Mol. Genet. 16, 1098–1112 (2007). https://doi.org/10.1093/hmg/ddm059CrossRef

135.

M.E. Freret, D.H. Gutmann, Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1. J. Neurosci. Res. 97, 45–56 (2019). https://doi.org/10.1002/jnr.24250CrossRef

136.

W.W. Pong, S.B. Higer, S.M. Gianino, R.J. Emnett, D.H. Gutmann, Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann. Neurol. 73, 303–308 (2013). https://doi.org/10.1002/ana.23813CrossRef

137.

A.C. Solga, W.W. Pong, K.Y. Kim, P.J. Cimino, J.A. Toonen, J. Walker, T. Wylie, V. Magrini, M. Griffith, O.L. Griffith, A. Ly, M.H. Ellisman, E.R. Mardis, D.H. Gutmann, RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia 17, 776–788 (2015) https://doi.org/10.1016/j.neo.2015.10.002

138.

C.Yu-Ju Wu, C.H. Chen, C.Y. Lin, L.Y. Feng, Y.C. Lin, K.C. Wei, C.Y. Huang, J.Y. Fang, P.Y. Chen, CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2. Neuro-oncology 22, 253–266 (2020). https://doi.org/10.1093/neuonc/noz189CrossRef

139.

Y. Pan, M. Xiong, R. Chen, Y. Ma, C. Corman, M. Maricos, U. Kindler, M. Semtner, Y.H. Chen, S. Dahiya, D.H. Gutmann, Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth. Genes Dev. 32, 491–496 (2018). https://doi.org/10.1101/gad.310797.117CrossRef

140.

Y.H. Chen, L.D. McGowan, P.J. Cimino, S. Dahiya, J.R. Leonard, D.Y. Lee, D.H. Gutmann, Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep. 10, 1899–1912 (2015). https://doi.org/10.1016/j.celrep.2015.02.041CrossRef

141.

J. Chatterjee, S. Sanapala, O. Cobb, A. Bewley, A.K. Goldstein, E. Cordell, X. Ge, J.R. Garbow, M.J. Holtzman, D.H. Gutmann, Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia. Nat. Commun. 12, 7122 (2021). https://doi.org/10.1038/s41467-021-27455-6CrossRef

142.

Y. Pan, J.D. Hysinger, T. Barron, N.F. Schindler, O. Cobb, X. Guo, B. Yalçın, C. Anastasaki, S.B. Mulinyawe, A. Ponnuswami, S. Scheaffer, Y. Ma, K.C. Chang, X. Xia, J.A. Toonen, J.J. Lennon, E.M. Gibson, J.R. Huguenard, L.M. Liau, J.L. Goldberg, M. Monje, D.H. Gutmann, NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature 594, 277–282 (2021). https://doi.org/10.1038/s41586-021-03580-6CrossRef

143.

K.R. Jessen, R. Mirsky, A.C. Lloyd, Schwann Cells: Development and Role in Nerve Repair, Cold Spring Harb. Perspect. Biol. 7, a020487 (2015) https://doi.org/10.1101/cshperspect.a020487

144.

H. Zheng, L. Chang, N. Patel, J. Yang, L. Lowe, D.K. Burns, Y. Zhu, Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer cell. 13, 117–128 (2008). https://doi.org/10.1016/j.ccr.2008.01.002CrossRef

145.

N.M. Joseph, J.T. Mosher, J. Buchstaller, P. Snider, P.E. McKeever, M. Lim, S.J. Conway, L.F. Parada, Y. Zhu, S.J. Morrison, The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer cell. 13, 129–140 (2008). https://doi.org/10.1016/j.ccr.2008.01.003CrossRef

146.

S. Parrinello, L.A. Noon, M.C. Harrisingh, P. Wingfield Digby, L.H. Rosenberg, C.A. Cremona, P. Echave, A.M. Flanagan, L.F. Parada, A.C. Lloyd, NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F. Genes Dev. 22, 3335–3348 (2008). https://doi.org/10.1101/gad.490608CrossRef

147.

K.J. Radomska, F. Coulpier, A. Gresset, A. Schmitt, A. Debbiche, S. Lemoine, P. Wolkenstein, J.M. Vallat, P. Charnay, P. Topilko, Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells. Cancer Discov. 9, 130–147 (2019). https://doi.org/10.1158/2159-8290.Cd-18-0156CrossRef

148.

F.L. Rice, G. Houk, J.P. Wymer, S.J.C. Gosline, J. Guinney, J. Wu, N. Ratner, M.P. Jankowski, S. La Rosa, M. Dockum, J.R. Storey, S.L. Carroll, P.J. Albrecht, V.M. Riccardi, The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin. PloS one 14, e0216527 (2019) https://doi.org/10.1371/journal.pone.0216527

149.

C.P. Liao, S. Pradhan, Z. Chen, A.J. Patel, R.C. Booker, L.Q. Le, The role of nerve microenvironment for neurofibroma development. Oncotarget 7, 61500–61508 (2016). https://doi.org/10.18632/oncotarget.11133CrossRef

150.

J. Korfhage, D.B. Lombard, Malignant peripheral nerve sheath tumors: From epigenome to bedside. Mol. Cancer Res. 17, 1417–1428 (2019). https://doi.org/10.1158/1541-7786.Mcr-19-0147CrossRef

151.

A.W. James, E. Shurell, A. Singh, S.M. Dry, F.C. Eilber, Malignant Peripheral Nerve Sheath Tumor. Surg. Oncol. Clin. N. Am. 25, 789–802 (2016). https://doi.org/10.1016/j.soc.2016.05.009CrossRef

152.

S.L. Carroll, M.S. Stonecypher, Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations. J. Neuropathol. Exp. Neurol. 63, 1115–1123 (2004). https://doi.org/10.1093/jnen/63.11.1115CrossRef

153.

M. Rahmatullah, A. Schroering, K. Rothblum, R.C. Stahl, B. Urban, D.J. Carey, Synergistic regulation of Schwann cell proliferation by heregulin and forskolin, Molecular and cellular biology 18, 6245–6252 (1998) https://doi.org/10.1128/mcb.18.11.6245

154.

S.L. Carroll, M.L. Miller, P.W. Frohnert, S.S. Kim, J.A. Corbett, Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J. neuroscience: official J. Soc. Neurosci. 17, 1642–1659 (1997). https://doi.org/10.1523/jneurosci.17-05-01642.1997CrossRef

155.

R.P. Huijbregts, K.A. Roth, R.E. Schmidt, S.L. Carroll, Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells. J. neuroscience: official J. Soc. Neurosci. 23, 7269–7280 (2003). https://doi.org/10.1523/jneurosci.23-19-07269.2003CrossRef

156.

M.S. Stonecypher, S.J. Byer, W.E. Grizzle, S.L. Carroll, Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors. Oncogene 24, 5589–5605 (2005). https://doi.org/10.1038/sj.onc.1208730CrossRef

157.

J.M. Eckert, S.J. Byer, B.J. Clodfelder-Miller, S.L. Carroll, Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells. Glia 57, 1501–1520 (2009). https://doi.org/10.1002/glia.20866CrossRef

158.

S.J. Kazmi, S.J. Byer, J.M. Eckert, A.N. Turk, R.P. Huijbregts, N.M. Brossier, W.E. Grizzle, F.M. Mikhail, K.A. Roth, S.L. Carroll, Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am. J. Pathol. 182, 646–667 (2013). https://doi.org/10.1016/j.ajpath.2012.11.017CrossRef

159.

S.N. Brosius, A.N. Turk, S.J. Byer, N.M. Brossier, L. Kohli, A. Whitmire, F.M. Mikhail, K.A. Roth, S.L. Carroll, Neuregulin-1 overexpression and Trp53 haploinsufficiency cooperatively promote de novo malignant peripheral nerve sheath tumor pathogenesis. Acta Neuropathol. 127, 573–591 (2014). https://doi.org/10.1007/s00401-013-1209-3CrossRef

160.

K.L. Carraway 3rd and L.C. Cantley, A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78, 5–8 (1994). https://doi.org/10.1016/0092-8674(94)90564-9CrossRef

161.

J.F. Longo, S.N. Brosius, L. Black, S.H. Worley, R.C. Wilson, K.A. Roth, S.L. Carroll, ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms. Cell. communication and signaling: CCS 17, 74 (2019). https://doi.org/10.1186/s12964-019-0388-5CrossRef

162.

Z. Wang, ErbB Receptors and Cancer, (Clifton, Methods in molecular biology. N J. ) 1652, 3–35 (2017). https://doi.org/10.1007/978-1-4939-7219-7_1CrossRef

163.

R. Huang, A. Fujimura, E. Nakata, S. Takihira, H. Inoue, S. Yoshikawa, T. Hiyama, T. Ozaki, A. Kamiya, Adrenergic signaling promotes the expansion of cancer stem-like cells of malignant peripheral nerve sheath tumors. Biochem. Biophys. Res. Commun. 557, 199–205 (2021). https://doi.org/10.1016/j.bbrc.2021.03.172CrossRef

164.

S. Li, Z. Chen, L.Q. Le, New insights into the neurofibroma tumor cells of origin. Neurooncol. Adv. 2, i13-i22 (2020) https://doi.org/10.1093/noajnl/vdz044

165.

D.Y. Lee, S.M. Gianino, D.H. Gutmann, Innate neural stem cell heterogeneity determines the patterning of glioma formation in children. Cancer cell. 22, 131–138 (2012). https://doi.org/10.1016/j.ccr.2012.05.036CrossRef

166.

F.C. Yang, D.A. Ingram, S. Chen, Y. Zhu, J. Yuan, X. Li, X. Yang, S. Knowles, W. Horn, Y. Li, S. Zhang, Y. Yang, S.T. Vakili, M. Yu, D. Burns, K. Robertson, G. Hutchins, L.F. Parada, D.W. Clapp, Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 135, 437–448 (2008). https://doi.org/10.1016/j.cell.2008.08.041CrossRef

167.

A. Bui, C. Jiang, R.M. McKay, L.J. Klesse, L.Q. Le, Insights into the Pathogenesis of NF1-Associated Neoplasms, JID innovations: skin science from molecules to population health 1, (2021) https://doi.org/10.1016/j.xjidi.2021.100044

168.

L.B. King, T. Boto, V. Botero, A.M. Aviles, B.M. Jomsky, C. Joseph, J.A. Walker, S.M. Tomchik, Developmental loss of neurofibromin across distributed neuronal circuits drives excessive grooming in Drosophila. PLoS Genet. 16, e1008920 (2020). https://doi.org/10.1371/journal.pgen.1008920CrossRef

169.

V. Pinna, V. Lanari, P. Daniele, F. Consoli, E. Agolini, K. Margiotti, I. Bottillo, I. Torrente, A. Bruselles, C. Fusilli, A. Ficcadenti, S. Bargiacchi, E. Trevisson, M. Forzan, S. Giustini, C. Leoni, G. Zampino, M.C. Digilio, B. Dallapiccola, M. Clementi, M. Tartaglia, A. De Luca, p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas. Eur. J. Hum. genetics: EJHG 23, 1068–1071 (2015). https://doi.org/10.1038/ejhg.2014.243CrossRef

170.

M. Upadhyaya, S.M. Huson, M. Davies, N. Thomas, N. Chuzhanova, S. Giovannini, D.G. Evans, E. Howard, B. Kerr, S. Griffiths, C. Consoli, L. Side, D. Adams, M. Pierpont, R. Hachen, A. Barnicoat, H. Li, P. Wallace, J.P. Van Biervliet, D. Stevenson, D. Viskochil, D. Baralle, E. Haan, V. Riccardi, P. Turnpenny, C. Lazaro, L. Messiaen, An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970–2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. Am. J. Hum. Genet. 80, 140–151 (2007). https://doi.org/10.1086/510781CrossRef

171.

C. Ejerskov, M. Gaustadnes, J.R. Ostergaard, K. Krogh, K. Thorsen, A.D. Borglum, A. Haagerup, Exploring associations between constipation, severity of neurofibromatosis type 1 and NF1 mutational spectrum. Sci. Rep. 11, 9179 (2021). https://doi.org/10.1038/s41598-021-87686-xCrossRef

172.

M. Scala, I. Schiavetti, F. Madia, C. Chelleri, G. Piccolo, A. Accogli, A. Riva, V. Salpietro, R. Bocciardi, G. Morcaldi, M. Di Duca, F. Caroli, A. Verrico, C. Milanaccio, G. Viglizzo, M. Traverso, S. Baldassari, P. Scudieri, M. Iacomino, G. Piatelli, C. Minetti, P. Striano, M.L. Garrè, P. De Marco, M.C. Diana, V. Capra, M. Pavanello, F. Zara, Genotype-Phenotype Correlations in Neurofibromatosis Type 1: A Single-Center Cohort Study. Cancers 13 (2021) https://doi.org/10.3390/cancers13081879

173.

H. Kehrer-Sawatzki, D.N. Cooper, Classification of NF1 microdeletions and its importance for establishing genotype/phenotype correlations in patients with NF1 microdeletions. Hum. Genet. 140, 1635–1649 (2021). https://doi.org/10.1007/s00439-021-02363-3CrossRef

174.

T. Johung, M. Monje, Neuronal activity in the glioma microenvironment. Curr. Opin. Neurobiol. 47, 156–161 (2017). https://doi.org/10.1016/j.conb.2017.10.009CrossRef

175.

D.P. Radin, S.E. Tsirka, Interactions between Tumor Cells, Neurons, and Microglia in the Glioma Microenvironment, Int. J. Mol. Sci. 21, (2020) https://doi.org/10.3390/ijms21228476

176.

M.L. Broekman, S.L.N. Maas, E.R. Abels, T.R. Mempel, A.M. Krichevsky, X.O. Breakefield, Multidimensional communication in the microenvirons of glioblastoma, Nature reviews. Neurology 14, 482–495 (2018). https://doi.org/10.1038/s41582-018-0025-8CrossRef

177.

S. Friedman, R. Levy, W. Garrett, D. Doval, Bondarde, S.J.C. Research, Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients. Cancer Res 69, 5056–5056 (2009)

178.

J. Infante, H.A. Burris, N. Lewis, A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17. (2007)

179.

M.W. Ronellenfitsch, P.N. Harter, M. Kirchner, C. Heining, B. Hutter, L. Gieldon, J. Schittenhelm, M.U. Schuhmann, M. Tatagiba, G. Marquardt, M. Wagner, V. Endris, C.H. Brandts, V.F. Mautner, E. Schröck, W. Weichert, B. Brors, A. von Deimling, M. Mittelbronn, J.P. Steinbach, D.E. Reuss, H. Glimm, A. Stenzinger, S. Fröhling, Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. J. Clin. Investig. 130, 2488–2495 (2020). https://doi.org/10.1172/jci130787CrossRef

180.

B. Weiss, B.C. Widemann, P. Wolters, E. Dombi, A. Vinks, A. Cantor, J. Perentesis, E. Schorry, N. Ullrich, D.H. Gutmann, J. Tonsgard, D. Viskochil, B. Korf, R.J. Packer, M.J. Fisher, Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro-oncology 17, 596–603 (2015). https://doi.org/10.1093/neuonc/nou235CrossRef

181.

N.J. Ullrich, S.P. Prabhu, A.T. Reddy, M.J. Fisher, R. Packer, S. Goldman, N.J. Robison, D.H. Gutmann, D.H. Viskochil, J.C. Allen, B. Korf, A. Cantor, G. Cutter, C. Thomas, J.P. Perentesis, T. Mizuno, A.A. Vinks, P.E. Manley, S.N. Chi, M.W. Kieran, A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro-oncology 22, 1527–1535 (2020). https://doi.org/10.1093/neuonc/noaa071CrossRef

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of nerves in neurofibromatosis type 1-related nervous system tumors

Abstract

Background

Conclusion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2022

Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis

CEP55 3’-UTR promotes epithelial–mesenchymal transition and enhances tumorigenicity of bladder cancer cells by acting as a ceRNA regulating miR-497-5p

Inhibition of PP2A by LB100 sensitizes bladder cancer cells to chemotherapy by inducing p21 degradation

ITGA2 induces STING expression in pancreatic cancer by inducing DNMT1 degradation

The LINC00152/miR-205-5p/CXCL11 axis in hepatocellular carcinoma cancer-associated fibroblasts affects cancer cell phenotypes and tumor growth

DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer